{
    "organizations": [],
    "uuid": "284fc43da4cdda9784ea2fb77da657a7bdfb33df",
    "author": "",
    "url": "https://www.reuters.com/article/brief-merrimack-says-dosed-first-patient/brief-merrimack-says-dosed-first-patient-in-randomized-phase-2-clinical-study-of-mm-121-idUSFWN1QG0T2",
    "ord_in_thread": 0,
    "title": "BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 26, 2018 / 12:22 PM / in 2 minutes BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121 Reuters Staff 1 Min Read Feb 26 (Reuters) - Merrimack Pharmaceuticals Inc: * MERRIMACK - ‍ DOSED FIRST PATIENT IN RANDOMIZED PHASE 2 CLINICAL STUDY OF MM-121 IN PATIENTS WITH POST-MENOPAUSAL METASTATIC BREAST CANCER​ * MERRIMACK PHARMA SAYS SHERLOC PHASE 2 STUDY ASSESSING MM-121 WITH DOCETAXEL VERSUS DOCETAXEL ALONE IS EXPECTED TO DELIVER TOP-LINE DATA IN H2 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-02-26T14:20:00.000+02:00",
    "crawled": "2018-02-26T14:25:55.025+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "say",
        "dosed",
        "first",
        "patient",
        "randomized",
        "phase",
        "clinical",
        "study",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "merrimack",
        "pharmaceutical",
        "inc",
        "merrimack",
        "dosed",
        "first",
        "patient",
        "randomized",
        "phase",
        "clinical",
        "study",
        "patient",
        "metastatic",
        "breast",
        "merrimack",
        "pharma",
        "say",
        "sherloc",
        "phase",
        "study",
        "assessing",
        "docetaxel",
        "versus",
        "docetaxel",
        "alone",
        "expected",
        "deliver",
        "data",
        "h2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}